"instanceType","versionIdentifier","uuid:ID","rationale","id"
"StudyVersion","2","d7d3c2fa-26a4-47b7-bd1c-519cb0b945fa","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
